Goal-directed treatment of osteoporosis in Europe (Q38246948)

1 September 2017

Goal-directed treatment of osteoporosis in Europe (English)

1 reference

1 September 2017

0 references

J A Kanis

1

1 reference

1 September 2017

E McCloskey

2

1 reference

1 September 2017

J Branco

3

1 reference

1 September 2017

M-L Brandi

4

1 reference

1 September 2017

E Dennison

5

1 reference

1 September 2017

J-P Devogelaer

6

1 reference

1 September 2017

S Ferrari

7

1 reference

1 September 2017

J-M Kaufman

8

1 reference

1 September 2017

S Papapoulos

9

1 reference

1 September 2017

J-Y Reginster

10

1 reference

1 September 2017

R Rizzoli

11

1 reference

1 September 2017

language of work or name

English

0 references

publication date

9 September 2014

1 reference

Osteoporosis International

1 September 2017

1 reference

1 September 2017

25

1 reference

1 September 2017

11

1 reference

1 September 2017

2533-2543

1 reference

https://scigraph.springernature.com/pub.10.1007/s00198-014-2787-1

1 September 2017

0 references

cites work

Treat-to-target for osteoporosis: is now the time?

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Goal-directed treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Cardiovascular protection and blood pressure reduction: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

The IDEAL cholesterol: lower is better

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

How evidence-based are the recommendations in evidence-based guidelines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Cholesterol limits lose their lustre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Target cardiovascular risk rather than cholesterol concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

A systematic review of hip fracture incidence and probability of fracture worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

A method to assess the proportion of treatment effect explained by a surrogate endpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

A meta-analysis of reference markers of bone turnover for prediction of fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Cortical porosity identifies women with osteopenia at increased risk for forearm fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Trabecular bone score: a noninvasive analytical method based upon the DXA image

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Theoretical implications of the biomechanical fracture threshold

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Assessment of fracture risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX(®).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Effect of alendronate for reducing fracture by FRAX score and femoral neck bone mineral density: the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Does osteoporosis therapy invalidate FRAX for fracture prediction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Has reimbursement of bone mineral density testing and anti-osteoporotic treatments improved management of osteoporosis in France?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Missed opportunities for osteoporosis treatment in patients hospitalized for hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EF

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

SCOPE: a scorecard for osteoporosis in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Goal-directed therapy in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Treatment failure in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Can Change in FRAX Score Be Used to “Treat to Target”? A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00198-014-2787-1

Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents

21 January 2018

1 reference

12 December 2020

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk

1 reference

12 December 2020

Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

ESC/EAS Guidelines for the management of dyslipidaemias

1 reference

12 December 2020

When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal

1 reference

12 December 2020

Predictive Value of BMD for Hip and Other Fractures

1 reference

12 December 2020

Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011

1 reference

12 December 2020

Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health

1 reference

12 December 2020

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

1 reference

12 December 2020

Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)

1 reference

12 December 2020

10.1007/S00198-014-2787-1

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference